{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:37:42Z","timestamp":1760099862640},"reference-count":80,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T00:00:00Z","timestamp":1143849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2006,4]]},"DOI":"10.1016\/j.clinthera.2006.04.006","type":"journal-article","created":{"date-parts":[[2006,6,7]],"date-time":"2006-06-07T21:13:22Z","timestamp":1149714802000},"page":"475-490","source":"Crossref","is-referenced-by-count":20,"title":["Once-monthly Ibandronate for postmenopausal Osteoporosis: Review of a new dosing regimen"],"prefix":"10.1016","volume":"28","author":[{"given":"Eunice Y.","family":"Pyon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2006.04.006_bib1","series-title":"Consensus development conference: Diagnosis, prophylaxis, and treatment of osteoporosis","first-page":"646","volume":"94","year":"1993"},{"key":"10.1016\/j.clinthera.2006.04.006_bib2","first-page":"1","article-title":"Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group","volume":"843","year":"1994","journal-title":"World Health Organ Tech Rep Ser."},{"key":"10.1016\/j.clinthera.2006.04.006_bib3","first-page":"1","article-title":"Diet, nutrition and the prevention of chronic diseases","volume":"916","year":"2003","journal-title":"World Health Organ Tech Rep Ser."},{"key":"10.1016\/j.clinthera.2006.04.006_bib4","author":"National Osteoporosis Foundation. Advocacy News & Updates. America's Bone Health"},{"key":"10.1016\/j.clinthera.2006.04.006_bib5","series-title":"Bone Health and Osteoporosis: A Report of the Surgeon General","year":"2004"},{"key":"10.1016\/j.clinthera.2006.04.006_bib6","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/S0140-6736(02)08657-9","article-title":"Epidemiology and outcomes of osteoporotic fractures","volume":"359","author":"Cummings","year":"2002","journal-title":"Lancet."},{"key":"10.1016\/j.clinthera.2006.04.006_bib7","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1046\/j.1532-5415.2002.50455.x","article-title":"Mortality, disability, and nursing home use for persons with and without hip fracture: A population-based study","volume":"50","author":"Leibson","year":"2002","journal-title":"J Am Geriatr Soc."},{"issue":"Suppl 8","key":"10.1016\/j.clinthera.2006.04.006_bib8","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1097\/00005131-200309001-00002","article-title":"Mortality risk after hip fracture. 2003","volume":"17","author":"Richmond","year":"2003","journal-title":"J Orthop Trauma."},{"key":"10.1016\/j.clinthera.2006.04.006_bib9","series-title":"Osteoporosis in Men: The Effects of Gender on Skeletal Health","first-page":"15","article-title":"Economic impact of fractures","author":"Tosteson","year":"1999"},{"key":"10.1016\/j.clinthera.2006.04.006_bib10","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1592\/phco.25.4.574.61031","article-title":"Treatment of postmenopausal osteoporosis","volume":"25","author":"Greenblatt","year":"2005","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinthera.2006.04.006_bib11","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11926-005-0012-0","article-title":"Oral antiresorptive therapy","volume":"7","author":"Pande","year":"2005","journal-title":"Curr Rheumatol Rep."},{"key":"10.1016\/j.clinthera.2006.04.006_bib12","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1055\/s-2005-869481","article-title":"Prevention of postmenopausal bone loss and treatment of osteoporosis","volume":"23","author":"Kleerekoper","year":"2005","journal-title":"Semin Reprod Med."},{"key":"10.1016\/j.clinthera.2006.04.006_bib13","series-title":"Pharmacotherapy: A Pathophysiologic Approach","first-page":"1645","article-title":"Osteoporosis and osteomalacia","author":"O'Connell","year":"2005"},{"key":"10.1016\/j.clinthera.2006.04.006_bib14","first-page":"462","article-title":"The use of bisphosphonates in the treatment of osteoporosis","volume":"17","author":"Delmas","year":"2005","journal-title":"Curr Opin Rheumatol."},{"key":"10.1016\/j.clinthera.2006.04.006_bib15","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2165\/00003495-199957010-00011","article-title":"Ibandronate","volume":"57","author":"Dooley","year":"1999","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2006.04.006_bib17","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00198-004-1612-7","article-title":"Ibandronate in osteoporosis: Preclinical data and rationale for intermittent dosing","volume":"15","author":"Bauss","year":"2004","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.clinthera.2006.04.006_bib18","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.clinthera.2005.04.005","article-title":"Optimizing the management of postmenopausal osteoporosis with bisphosphonates: The emerg ing role of intermittent therapy","volume":"27","author":"Miller","year":"2005","journal-title":"Clin Ther."},{"key":"10.1016\/j.clinthera.2006.04.006_bib19","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/jbmr.5650060915","article-title":"BM 21.0955, a potent new bisphosphonate to inhibit bone resorption","volume":"6","author":"Muhlbauer","year":"1991","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.clinthera.2006.04.006_bib20","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1177\/0091270004267594","article-title":"Ibandronate: A clinical pharmacological and pharmacokinetic up date","volume":"44","author":"Barrett","year":"2004","journal-title":"J Clin Pharmacol."},{"key":"10.1016\/j.clinthera.2006.04.006_bib21","first-page":"289","article-title":"Ibandronate: Serum kinetics, tissue distribution and bind ing to bone following intravenous bolus injection","volume":"70","author":"Bauss","year":"2002","journal-title":"Calcif Tissue Int."},{"key":"10.1016\/j.clinthera.2006.04.006_bib22","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1359\/jbmr.1999.14.10.1768","article-title":"Intermittent and continuous administration of the bisphosphonate ibandronate in ovariohysterectomized beagle dogs: Effects on bone morphometry and mineral properties","volume":"14","author":"Monier-Faugere","year":"1999","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.clinthera.2006.04.006_bib23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S8756-3282(02)00923-7","article-title":"Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys","volume":"32","author":"Smith","year":"2003","journal-title":"Bone"},{"key":"10.1016\/j.clinthera.2006.04.006_bib24","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chestnut","year":"2004","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.clinthera.2006.04.006_bib25","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.1210\/jc.2004-1750","article-title":"Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: Results from the monthly oral pilot study","volume":"90","author":"Reginster","year":"2005","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.clinthera.2006.04.006_bib26","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1359\/JBMR.050313","article-title":"Monthly oral ibandronate therapy in postmenopausal osteo porosis: 1-Year results from the MOBI LE study","volume":"20","author":"Miller","year":"2005","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.clinthera.2006.04.006_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/ard.2005.044958","article-title":"Efficacy and tolerability of oncemonthly oral ibandronate in post menopausal osteoporosis: 2-Year results from the MOBILE study","author":"Reginster","year":"2006","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.clinthera.2006.04.006_bib28","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1359\/jbmr.2001.16.10.1871","article-title":"Ibandronate: A comparison of oral daily dosing versus intermittent dos ing in postmenopausal osteoporosis","volume":"16","author":"R\u00fcs","year":"2001","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.clinthera.2006.04.006_bib29","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1136\/ard.62.10.969","article-title":"Intravenous ibandronate injections given every three months: A new treatment option to prevent bone loss in postmenopausal women","volume":"62","author":"Stakkestad","year":"2003","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.clinthera.2006.04.006_bib30","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.bone.2004.01.007","article-title":"Efficacy and safety of ibandronate given by intravenous injec tion once every 3 months","volume":"34","author":"Adami","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.clinthera.2006.04.006_bib31","first-page":"990","article-title":"Total administered dose of ibandronate determines its effects on bone mass and architecture in ovariectomized aged rats","volume":"29","author":"Bauss","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clinthera.2006.04.006_bib32","first-page":"2200","article-title":"Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats","volume":"29","author":"Bauss","year":"2002","journal-title":"J Rheumatol."},{"key":"10.1016\/j.clinthera.2006.04.006_bib33","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1359\/JBMR.040809","article-title":"Intermittent ibandronate preserves bone quality and bone strength in the lumbar spine after 16 months of treatment in the ovariectomized cynomolgus monkey","volume":"19","author":"Muller","year":"2004","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.clinthera.2006.04.006_bib34","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1345\/aph.1E357","article-title":"Discovery, clinical development, and therapeutic uses of bisphosphonates","volume":"39","author":"Licata","year":"2005","journal-title":"Ann Pharmacother."},{"key":"10.1016\/j.clinthera.2006.04.006_bib35","series-title":"Boniva [package insert]","year":"2005"},{"key":"10.1016\/j.clinthera.2006.04.006_bib36","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S8756-3282(03)00033-4","article-title":"The efficacy of 48-week oral ibandronate treatment in post menopausal osteoporosis when taken 30 versus 60 minutes before breakfast","volume":"32","author":"Tanko","year":"2003","journal-title":"Bone"},{"key":"10.1016\/j.clinthera.2006.04.006_bib37","series-title":"27th Annual Meeting of the American Society for Bone and Mineral Research","article-title":"Once-monthly oral ibandronate is at least as effec tive as daily oral ibandronate in postmenopausal osteoporosis: 2-Year findings from MOBILE","author":"McClung","year":"2005"},{"key":"10.1016\/j.clinthera.2006.04.006_bib38","series-title":"27th Annual Meeting of the American Society for Bone and Mineral Research","article-title":"Once-monthly oral ibandronate effectively normalizes biochemical markers of bone resorption in postmenopausal osteoporosis: MOBILE 2-year analysis","author":"Miller","year":"2005"},{"key":"10.1016\/j.clinthera.2006.04.006_bib39","series-title":"27th Annual Meeting of the American Society for Bone and Mineral Research","article-title":"Large proportions of women with postmenopausal osteo porosis respond to once-monthly oral ibandronate: 2-Year results from MOBILE","author":"Reckner","year":"2005"},{"key":"10.1016\/j.clinthera.2006.04.006_bib40","series-title":"Poster presented at 27th Annual Meeting of the American Society for Bone and Mineral Research","article-title":"Rationale and design of the MOTION study (Monthly Oral Therapy with Ibandronate for Osteoporosis iNtervention)","author":"Cosman","year":"2005"},{"key":"10.1016\/j.clinthera.2006.04.006_bib41","first-page":"1","article-title":"Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis","volume":"12","author":"Schnitzer","year":"2000","journal-title":"Aging (Milano)"},{"key":"10.1016\/j.clinthera.2006.04.006_bib42","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00223-002-2011-8","article-title":"The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis","volume":"71","author":"Brown","year":"2002","journal-title":"Calcif Tissue Int."},{"key":"10.1016\/j.clinthera.2006.04.006_bib43","series-title":"Fosamax [package insert]","year":"2005"},{"key":"10.1016\/j.clinthera.2006.04.006_bib44","series-title":"Actonel [package insert]","year":"2005"},{"key":"10.1016\/j.clinthera.2006.04.006_bib45","series-title":"27th Annual Meeting of the American Society for Bone and Mineral Research","article-title":"Once-monthly oral ibandronate is safe and well tolerated in women with postmenopausal osteoporosis: MOBILE 2-year analysis","author":"Lewiecki","year":"2005"},{"key":"10.1016\/j.clinthera.2006.04.006_bib46","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","article-title":"Osteonecrosis of the jaws associated with the use of bis phosphonates: A review of 63 cases","volume":"62","author":"Ruggiero","year":"2004","journal-title":"J Oral Maxillofac Surg."},{"key":"10.1016\/j.clinthera.2006.04.006_bib47","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1056\/NEJM200507073530120","article-title":"Osteonecrosis of the jaw and bisphosphonates","volume":"353","author":"Maerevoet","year":"2005","journal-title":"N Engl J Med."},{"key":"10.1016\/j.clinthera.2006.04.006_bib48","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1600-0714.2004.00269.x","article-title":"Avascularjaw osteonecrosis in association with cancer chemotherapy: Series of 10 cases","volume":"34","author":"Bagan","year":"2005","journal-title":"J Oral Pathol Med."},{"key":"10.1016\/j.clinthera.2006.04.006_bib50","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00198-003-1502-4","article-title":"Compliance with pharmacologic therapy for osteoporosis","volume":"14","author":"Yood","year":"2003","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.clinthera.2006.04.006_bib51","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.maturitas.2004.02.005","article-title":"Compliance with drug therapies for the treatment and prevention of osteoporosis","volume":"48","author":"McCombs","year":"2004","journal-title":"Maturitas"},{"key":"10.1016\/j.clinthera.2006.04.006_bib52","series-title":"39th ASHP Midyear Clinical Meeting and Exhibits","article-title":"Adherence and persistence associated with the pharmacologic treatment of osteoporosis","author":"Boccuzzi","year":"2004"},{"key":"10.1016\/j.clinthera.2006.04.006_bib53","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0002-9343(03)00362-0","article-title":"Early discontinuation of treatment for osteoporosis","volume":"115","author":"Tosteson","year":"2003","journal-title":"Am J Med."},{"key":"10.1016\/j.clinthera.2006.04.006_bib54","first-page":"1","article-title":"Treatment of osteoporosis with bisphosphonates: Do compliance and persis tence matter?","author":"Reginster","year":"2004","journal-title":"Business Briefings: LongTerm Healthcare."},{"key":"10.1016\/j.clinthera.2006.04.006_bib55","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1016\/S0149-2918(03)80222-9","article-title":"The impact of reducing dose frequency on health outcomes","volume":"25","author":"Richter","year":"2003","journal-title":"Clin Ther."},{"key":"10.1016\/j.clinthera.2006.04.006_bib56","first-page":"856","article-title":"Effect of dosing frequency on bisphosphonate medication adher ence in a large longitudinal cohort of women","volume":"80","author":"Recker","year":"2005"},{"key":"10.1016\/j.clinthera.2006.04.006_bib57","series-title":"27th Annual Meeting of the American Society for Bone and Mineral Research","article-title":"BALTO I: Women treated for osteoporosis rate preference and convenience for once-monthly ibandronate versus once-weekly alendronate","author":"Emkey","year":"2005"},{"key":"10.1016\/j.clinthera.2006.04.006_bib58","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1185\/030079905X74862","article-title":"Patient preference for oncemonthly ibandronate versus once weekly alendronate in a randomized, open-label, cross-over trial: The Boniva Alendronate Trial in Osteoporosis (BALTO)","volume":"21","author":"Emkey","year":"2005","journal-title":"Curr Med Res Opin."},{"key":"10.1016\/j.clinthera.2006.04.006_bib59","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.clinthera.2005.08.006","article-title":"Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom","volume":"27","author":"De Cock","year":"2005","journal-title":"Clin Ther."},{"key":"10.1016\/j.clinthera.2006.04.006_bib60","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s00520-005-0828-1","article-title":"Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy","volume":"13","author":"De Cock","year":"2005","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clinthera.2006.04.006_bib61","series-title":"27th Annual Meeting of the American Society for Bone and Mineral Research","article-title":"Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: Implications of improved persistence with ibandronate","author":"Ettinger","year":"2005"},{"issue":"Suppl 7","key":"10.1016\/j.clinthera.2006.04.006_bib62","first-page":"S2","article-title":"Clinical and economic impact of adherence to osteoporosis medication","volume":"14","author":"Caro","year":"2003","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.clinthera.2006.04.006_bib63","series-title":"Red Book: August 2005 Update","year":"2005"},{"key":"10.1016\/j.clinthera.2006.04.006_bib64","series-title":"2005 Red Book","year":"2005"},{"key":"10.1016\/j.clinthera.2006.04.006_bib65","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1210\/jc.85.11.4118","article-title":"Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial","volume":"85","author":"Black","year":"2000","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.clinthera.2006.04.006_bib66","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2006.04.006_bib67","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1359\/JBMR.040920","article-title":"Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: A randomized double-blind study","volume":"20","author":"Rosen","year":"2005","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.clinthera.2006.04.006_bib68","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1185\/030079905X41390","article-title":"How useful are measures of BMD and bone turnover?","volume":"21","author":"Miller","year":"2005","journal-title":"Curr Med Res Opin."},{"key":"10.1016\/j.clinthera.2006.04.006_bib69","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1359\/JBMR.050217","article-title":"How to interpret surrogate markers of efficacy in osteoporosis","volume":"20","author":"Eastell","year":"2005","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.clinthera.2006.04.006_bib70","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1359\/jbmr.2003.18.6.1146","article-title":"Surrogates for fracture endpoints in clinical trials","volume":"18","author":"Khosla","year":"2003","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.clinthera.2006.04.006_bib71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clinthera.2004.12.020","article-title":"The bone quality framework: Determinants of bone strength and their interrelationships, and implications for osteoporosis management","volume":"27","author":"Felsenberg","year":"2005","journal-title":"Clin Ther."},{"key":"10.1016\/j.clinthera.2006.04.006_bib72","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0889-8529(02)00024-5","article-title":"Summary of meta-analyses of therapies for postmenopausal os teoporosis and the relationship between bone density and fractures","volume":"31","author":"Guyatt","year":"2002","journal-title":"Endocrinol Metab Clin North Am."},{"key":"10.1016\/j.clinthera.2006.04.006_bib73","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1210\/jc.85.1.231","article-title":"Antifracture efficacy of antiresorptive agents are related to changes in bone density","volume":"85","author":"Wasnich","year":"2000","journal-title":"J Clin Endrocrinol Metab."},{"key":"10.1016\/j.clinthera.2006.04.006_bib74","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1210\/jc.87.4.1586","article-title":"Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents","volume":"87","author":"Hochberg","year":"2002","journal-title":"J Clin Endrocrinol Metab"},{"key":"10.1016\/j.clinthera.2006.04.006_bib75","first-page":"379","article-title":"The roles of bone mineral density, bone turnover, and other properties in reducing fracture risk during antiresorptive therapy","volume":"80","author":"Epstein","year":"2005"},{"key":"10.1016\/j.clinthera.2006.04.006_bib76","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11914-005-0018-6","article-title":"Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction","volume":"3","author":"Miller","year":"2005","journal-title":"Curr Osteoporos Rep."},{"key":"10.1016\/j.clinthera.2006.04.006_bib77","series-title":"27th Annual Meeting of the American Society for Bone and Mineral Research","article-title":"Treatment-related changes in BMD are not associated with the occurrence of a fragility fracture while on risedronate therapy","author":"Lindsay","year":"2005"},{"key":"10.1016\/j.clinthera.2006.04.006_bib78","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/annonc\/mdh173","article-title":"Oral ibandronate for the treatment of metastatic bone disease in breast cancer: Efficacy and safety results from a randomized, double-blind, placebo-controlled trial","volume":"15","author":"Tripathy","year":"2004","journal-title":"Ann Oncol."},{"key":"10.1016\/j.clinthera.2006.04.006_bib79","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pain.2004.07.011","article-title":"Oral ibandronate improves bone pain and preserves quality of life in pa tients with skeletal metastases due to breast cancer","volume":"111","author":"Body","year":"2004","journal-title":"Pain"},{"key":"10.1016\/j.clinthera.2006.04.006_bib80","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/annonc\/mdg367","article-title":"Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases","volume":"14","author":"Body","year":"2003","journal-title":"Ann Oncol."},{"key":"10.1016\/j.clinthera.2006.04.006_bib81","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.ejca.2004.03.025","article-title":"Improved quality of life after long term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer","volume":"40","author":"Diel","year":"2004","journal-title":"Eur J Cancer."},{"key":"10.1016\/j.clinthera.2006.04.006_bib82","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1016\/j.clinthera.2004.12.010","article-title":"Review of ibandronate in the treatment of metastatic bone disease: Experience from phase III trials","volume":"26","author":"Tripathy","year":"2004","journal-title":"Clin Ther."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291806000944?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291806000944?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,16]],"date-time":"2019-01-16T01:55:16Z","timestamp":1547603716000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291806000944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4]]},"references-count":80,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,4]]}},"alternative-id":["S0149291806000944"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2006.04.006","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2006,4]]}}}